This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MONDON, C. E. Articles by FRIGERI, L. G. Search for Related Content PubMed PubMed Citation Articles by MONDON, C. E. Articles by FRIGERI, L. G.

Amino-Terminal Peptide of Growth Hormone Enhances Insulin Action in Normal Rats^*

Department of Medicine, Stanford University School of Medicine, and Geriatric Research Education and Clinical Center, Veterans Administration Medical Center Pah Alto, California 94304
the Whittier Institute for Diabetes and Endocrinology La Jolla, California 92037

Address requests for reprints to: Carl E. Mondon, Ph.D., Veterans Administration Medical Center, GRECC/182B, 3801 Miranda Avenue, Palo Alto, California 94304.

Abstract

Earlier studies demonstrated that the 20K-dalton variant of human GH (hGH), which differs from hGH by deletion of the amino acid residues 32–46, has decreased insulinlike activity. The current study assessed whether a peptide representing this deleted region could enhance insulin-stimulated glucose uptake in the intact rat and if this effect was localized in liver and/or muscle. Peptides hGH-(32–46) and rat GH-(32–45) were used in these studies. Assessment of the action of a peptide was done by determining its effect on the steady state serum glucose (SSSG) concentration during an insulin suppression test. Glucose was infused alone and with two rates of infusion of insulin. The data indicated that neither of the GH peptides affected SSSG in the absence of exogenously administered insulin or at low (40 µU/ml) serum levels of insulin, but when serum insulin was increased to 77 µU/ml, a significant (P < 0.05) decrease in SSSG was produced by the peptides. In subsequent studies isolated liver and hind limb skeletal muscle were perfused with a solution of hGH-(32–46). Basal glucose release from the liver was suppressed by both hGH-(32–46) and insulin alone, and this decrease was not enhanced by combining insulin with hGH-(32–46). Glucose uptake by skeletal muscle, expressed as a metabolic clearance constant (k), was enhanced by infusion of insulin and further increased with added peptide. Basal uptake was 6.67 µl/min-g muscle; uptake was 8.17 µl/ min-g (P < 0.01) after addition of 128 µU/ml insulin. This increased still farther to 9.24 µl/min.g (P < 0.05) when peptide was administered with insulin. These findings suggest that GH peptides independently suppress glucose outflow from the liver and potentiate insulin action by facilitating glucose uptake by peripheral tissues. (Endocrinology 123: 827–833, 1988)

Footnotes

^* This work was supported by the VA Research Services.

Received December 14, 1987.

This article has been cited by other articles:

				E Juarez-Aguilar, F Castro-Munozledo, N. Guerra-Rodriguez, D Resendez-Perez, H. Martinez-Rodriguez, H. Barrera-Saldana, and W Kuri-Harcuch Functional domains of human growth hormone necessary for the adipogenic activity of hGH/hPL chimeric molecules J. Cell Sci., January 9, 1999; 112(18): 3127 - 3135. [Abstract] [PDF]